Regentis Biomaterials Ltd. Stock-Based Compensation
Regentis Biomaterials Ltd. (RGNT) reported Stock-Based Compensation of $7.04 million for the 12-month period ending 2025-12-31, per its 20-F/A filed 2026-02-27.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-02-27
| Period end | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|
| 2025-12-31 | $7.04M 20-F/A · filed 2026-02-27 |